Roy Walford spent 35 years building the theoretical and animal research foundation for calorie restriction with optimal nutrition. He died in 2004. Luigi Fontana spent the 20 years after that testing the framework in humans.

They did not overlap for long. But the research lineage is direct.

The Gap Walford Left

Walford’s work — the rodent studies, the primate literature, the Biosphere 2 data — established that calorie restriction with adequate nutrition extended lifespan in every model organism tested. The human data was thin. Biosphere 2 produced compelling cardiovascular outcomes but was not a controlled trial. It was a closed ecosystem with eight subjects and involuntary food scarcity.

The question the field needed answered: what happens when you take healthy, non-obese humans, control their caloric intake at a moderate deficit, ensure nutritional adequacy, and measure outcomes for years? Not in animals. Not in a sealed desert habitat. In a clinic.

Fontana built the infrastructure to answer it.

Washington University: The Observational Study

Starting in the early 2000s at Washington University School of Medicine in St. Louis, Fontana and John Holloszy recruited members of the Calorie Restriction Society — people who had been voluntarily practicing long-term calorie restriction on their own — and compared their physiological markers to sedentary controls and endurance athletes.

The 2004 PNAS paper was the first major output. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. The title is not hedged.

CR practitioners had significantly lower carotid intima-media thickness — the structural marker of arterial wall thickening that precedes atherosclerosis — than age-matched controls eating standard Western diets. Total cholesterol, LDL, triglycerides, and blood pressure were all lower. Fasting insulin was dramatically reduced.

The CR group was not running a pharmaceutical intervention. They were eating less food, more carefully.

A 2006 follow-up measured diastolic cardiac function — the heart’s ability to relax and fill between beats, which declines with normal aging. The CR group’s diastolic function matched people ten years younger. The mechanism appears to be reduced visceral fat, lower inflammatory load, and improved metabolic signaling rather than any single nutrient.

The IGF-1 Finding

One of Fontana’s most clinically significant findings was not the cardiovascular data. It was what calorie restriction failed to do.

In model organisms, calorie restriction reduces circulating insulin-like growth factor 1 (IGF-1). Lower IGF-1 is associated with extended lifespan in yeast, worms, flies, and mice. The expectation was that human CR practitioners would show the same reduction.

They did not — or not fully. Fontana et al. found that long-term calorie restriction without protein restriction did not lower IGF-1 to the levels seen in calorie-plus-protein-restricted organisms. When they compared CR practitioners to vegans eating similar calorie totals, the vegans had significantly lower IGF-1 — despite similar caloric restriction.

The difference was protein intake. CR practitioners eating adequate animal protein maintained higher IGF-1.

This finding has significant implications for how the CRON framework operates in practice. Walford’s protocol emphasizes protein adequacy — 30g+ per meal, anchor proteins at every sitting. That may be the right target for body composition and muscle preservation in a caloric deficit. It may also mean that the IGF-1-mediated longevity pathway requires something different than what CRON optimizes for.

Fontana does not resolve this tension. He surfaces it. The 2014 Cell Metabolism paper he co-authored (with Valter Longo’s group) found that high protein intake in adults under 65 was associated with higher cancer risk and overall mortality — an association that disappeared in adults over 65, where higher protein appeared protective. The data suggests the optimal protein target may not be static across a lifespan.

The CRON protocol targets protein adequacy. Fontana’s data raises the question of whether “adequate” means the same thing at 40, 55, and 70.

CALERIE Phase 2

The observational study was informative but limited — self-selected participants, no randomization, no controlled caloric prescription. CALERIE Phase 2 addressed those gaps.

218 healthy, non-obese adults. Randomized 2:1 to 25% calorie restriction or ad libitum eating. 24 months. Three sites including Washington University, where Fontana served as principal investigator.

The cardiometabolic outcomes, published in Lancet Diabetes & Endocrinology in 2019: CR reduced cardiovascular disease risk factors significantly. Reductions in blood pressure, LDL cholesterol, metabolic syndrome components. The effect size at two years was meaningful — comparable in some markers to pharmaceutical intervention, without pharmaceutical intervention.

The 2016 Aging Cell paper on IGF-1 and cortisol confirmed the IGF-1 reduction in the controlled trial setting. The inflammation and immunity paper found that 25% CR inhibited inflammatory pathways without impairing cellular immune function — a finding that mattered because early concerns about CR included immune suppression.

Body composition findings: lean mass was preserved. The concern that calorie restriction wastes muscle did not materialize in the trial data. With adequate protein and continued activity, the deficit came predominantly from fat mass.

The quality of life data showed improved mood, sleep, sexual function, and general health at 24 months. The commonly cited objection — that CR is too miserable to sustain — was not supported.

The Molecular Mechanism Work

Beyond the clinical outcomes, Fontana’s lab contributed molecular data on how CR affects gene expression. A 2013 Aging Cell paper found that calorie restriction in humans inhibits the PI3K/AKT/mTOR pathway and induces a younger transcription profile in skeletal muscle. The CR subjects’ skeletal muscle gene expression pattern resembled younger tissue. This is the molecular signature of slowed biological aging.

The 2022 Nature Reviews Molecular Cell Biology review, co-authored with Dudley Lamming and Cara Green, is the most comprehensive current synthesis of how dietary restriction works at the molecular level — covering mTOR, AMPK, sirtuins, IGF-1/insulin signaling, and the interactions between them. It is the reference paper for understanding what CRON is actually doing at the cellular level.

What Fontana’s Work Establishes

Twenty years of human data from Washington University and CALERIE Phase 2 produces a consistent picture:

  • Moderate calorie restriction in non-obese humans (25% reduction from maintenance) produces significant cardiovascular benefit over two years
  • Inflammatory markers improve
  • IGF-1 is reduced — with implications for cancer risk that depend on age and protein intake
  • Lean mass is preserved with adequate protein
  • Quality of life does not degrade and in controlled trials shows improvement
  • The molecular signature of CR in human skeletal muscle resembles younger tissue

What Fontana’s work does not establish: optimal calorie targets, optimal protein levels across the lifespan, or the point at which additional restriction produces diminishing or negative returns. The Ageing Research Reviews paper co-authored with Leanne Redman and Most explicitly acknowledges these gaps.

The data supports moderate, nutritionally adequate calorie restriction as a health intervention. Fontana’s contribution is making that claim with controlled human trial evidence rather than animal models and extrapolation.

Walford built the framework. Fontana tested it. The framework held.

Further reading: